CorMedix Inc

CorMedix Inc is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. CorMedix Inc is not a good value stock. CorMedix Inc is not a good growth stock. CorMedix Inc is a mediocre stock to choose.
Log in to see more information.
CorMedix, Inc. operates as a pharmaceutical and medical device company, which seeks to in-license, d...
CRMD Fundamental Data by TradingView

News

CorMedix announces new commercial agreement
CorMedix announces new commercial agreement

Seeking Alpha - Healthcare CorMedix announces new commercial agreement...\n more…

CorMedix enters multiyear commercial supply contract
CorMedix enters multiyear commercial supply contract

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

CorMedix Inc. Announces New Commercial Agreement
CorMedix Inc. Announces New Commercial Agreement

Globe Newswire BERKELEY HEIGHTS, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and...\n more…

Here's Why CorMedix (CRMD) Is a Great 'Buy the Bottom' Stock Now
Here's Why CorMedix (CRMD) Is a Great 'Buy the Bottom' Stock Now

Zacks Investment Research Shares of CorMedix (CRMD) have been struggling lately and have lost 7.7% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock...\n more…

CorMedix (CRMD) Is Up 10.44% in One Week: What You Should Know
CorMedix (CRMD) Is Up 10.44% in One Week: What You Should Know

Zacks Investment Research Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell...\n more…

Wall Street Analysts Think CorMedix (CRMD) Could Surge 117.77%: Read This Before Placing a Bet
Wall Street Analysts Think CorMedix (CRMD) Could Surge 117.77%: Read This Before Placing a Bet

Zacks Investment Research CorMedix (CRMD) closed the last trading session at $5.74, gaining 45.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street...\n more…